Medical Marijuana, Inc. CEO Featured on Seeking Alpha’s CEO Interviews Podcast

Medical Marijuana, Inc. CEO Featured on Seeking Alpha’s CEO Interviews Podcast

SAN DIEGO — via NewMediaWireMedical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its CEO Blake Schroeder was featured on an episode of Seeking Alpha’s CEO Interviews podcast discussing the current landscape of cannabis stocks.

The November 17, 2021 episode entitled “Making Sense Of Cannabis Stocks” featured a panel of top cannabis industry leaders, including Schroeder, discussing recent pending cannabis legislation and financial news as well as the many challenges and opportunities that currently exist for businesses in the cannabis industry. Schroeder highlighted the many first-mover milestones Medical Marijuana, Inc. has achieved over the years as well as where the Company is headed. He also elaborated on his optimism for the impact of several different legislative moves that could help the cannabis industry see exponential growth within the next few years.

“It is an honor to be invited to speak on Seeking Alpha’s podcast and a pleasure to participate in such an insightful discussion with seasoned industry professionals who, like us, are also working tirelessly to ensure free access to cannabis products in the US and around the world,” said Medical Marijuana, Inc. CEO, Blake Schroeder.

According to New Frontier Data, the US is projected to reach $51 billion in legal cannabis sales by 2025. In addition, Grand View Research has reported that the global legal marijuana market size is expected to reach $70.6 billion by 2028.

About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.


  • New Jersey Entrepreneurs bring social equity company REEForm to East Coast
    Social justice in cannabis is a popular topic, but actual change is elusive. Two New Jersey cannabis entrepreneurs built a business around making a difference in their community. They’re trying to deliver on the promise of social equity in cannabis. On September 14, New Jerseyians gathered at the Doubletree Hilton in Newark to learn about…
  • Head of NORML optimistic on cannabis banking through NDAA
    While defense bills don’t usually interest cannabis advocates, an amendment added by Representative Ed Perlmutter (D-CO) included the language of the SAFE Banking Act in the NDAA. With the standalone bill stalled in the Senate Banking Committee, an amendment to the “must-pass” legislation could be the key.
  • Advocate responds to SD high court overturning adult-use cannabis
    South Dakota’s highest court sided with the state’s governor today in declaring an amendment legalizing cannabis invalid. Amendment A, which passed with 54% support, would have legalized cannabis for anyone over 21.
  • Organizer says next steps on Ohio adult-use cannabis by month’s end
    Ohio attorney Thomas Haren, a representative of the “Coalition to Regulate Marijuana Like Alcohol,” said he expects that enough signatures will be gathered to move a proposal forward that would allow for adult use, sale, and possession of marijuana in Ohio.
  • Montana regulators will reverse proposed CBD, dispensary worker rules
    The Montana Department of Revenue told lawmakers this week that it will strike a pair of proposed rules implementing the state’s fledgling recreational marijuana program after hearing considerable input from members of the public, the cannabis industry and legislators who warned that the rules veered from the intent of House Bill 701, an act passed this session regulating the adult-use pot.
  • Cannabis prices soar in Louisiana due to regulatory bottleneck
    A regulatory bottleneck in Louisiana’s medical marijuana supply chain has inflated costs far beyond the prices found in other states, according to industry experts who testified at the Louisiana Legislature’s Medical Marijuana Commission meeting Thursday.
  • Critics say AZ ‘social equity’ program makes Big Cannabis even richer
    “This is a program that, as currently written, is designed to fail,” attorney Julie Gunnigle said to Arizona Mirror. Gunnigle up until recently worked for Arizona’s Chapter of NORML, an organization that pushes for the reform of marijuana laws across the United States.
  • Bipartisan bill to reduce Wisconsin cannabis fines introduced
    Wisconsin legislators are taking another crack at a bipartisan push to achieve cannabis reform in the state. A new piece of legislation, co-authored by Rep. Shae Sortwell (R-Gibson), Rep. Sylvia Ortiz-Valez (D-Milwaukee), Sen. Lena Taylor (D-Milwaukee) and Sen. Kathleen Bernier (R- Chippewa Falls), reduces existing penalties for cannabis possession.
  • Ret. Navy SEAL: Biden should support medical cannabis research bill
    Cannabis is just another bullet in the bandolier, and I believe it has had a positive impact. It helps treat PTSD symptoms like anxiety, fear and flashbacks. Unfortunately, our military is still culturally behind and bears real animus toward the plant.
  • Ohio senators mulling major revisions to medical cannabis system
    Ohio senators have filed legislation that represents a broad revision of the state’s medical marijuana system. Among the changes is language expanding access to the drug if a physician “reasonably” believes their patient’s symptoms would be relieved or they would otherwise benefit from marijuana.